{
  "id": 9155621,
  "title": "Celldex's hives drug faces safety questions despite Phase 3 successes",
  "url": "https://urgent.news/2026/09/22/celldexs-hives-drug-faces-safety-questions-despite-phase-3-successes",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-22T15:31:09.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/celldexs-hives-drug-faces-safety-questions-despite-phase-3-successes/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Celldex said its experimental treatment barzolvolimab hit its primary endpoint in two Phase 3 trials, even as the readout raised safety concerns on two life-threatening cases of allergic reaction following administration of the drug. The ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}